- Title
- Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer
- Creator
- Matthews, Bayley G.; Bowden, Nikola A.; Wong-Brown, Michelle W.
- Relation
- Cancers Vol. 13, Issue 23, no. 5993
- Publisher Link
- http://dx.doi.org/10.3390/cancers13235993
- Publisher
- MDPI AG
- Resource Type
- journal article
- Date
- 2021
- Description
- High-grade serous ovarian cancer (HGSOC) is the most common ovarian cancer subtype, and the overall survival rate has not improved in the last three decades. Currently, most patients develop recurrent disease within 3 years and succumb to the disease within 5 years. This is an important area of research, as the major obstacle to the treatment of HGSOC is the development of resistance to platinum chemotherapy. The cause of chemoresistance is still largely unknown and may be due to epigenetics modifications that are driving HGSOC metastasis and treatment resistance. The identification of epigenetic changes in chemoresistant HGSOC enables the development of epigenetic modulating drugs that may be used to improve outcomes. Several epigenetic modulating drugs have displayed promise as drug targets for HGSOC, such as demethylating agents azacitidine and decitabine. Others, such as histone deacetylase inhibitors and miRNA-targeting therapies, demonstrated promising preclinical results but resulted in off-target side effects in clinical trials. This article reviews the epigenetic modifications identified in chemoresistant HGSOC and clinical trials utilizing epigenetic therapies in HGSOC.
- Subject
- high-grade serous ovarian cancer; chemoresistance; epigenetic modifications; DNA methylation; histone acetylation; microRNA; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1470985
- Identifier
- uon:48589
- Identifier
- ISSN:2072-6694
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 789
- Visitors: 787
- Downloads: 0